TEE
TXMD icon

Tibra Equities Europe’s TherapeuticsMD TXMD Stock Holding History

Tibra Equities Europe’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,354
Closed -$817K – 431
2019
Q1 		$817K Buy
+3,354
New +$887K 0.08% 195

Other funds holding TXMD

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tibra Equities Europe's TXMD Position: Q2 2019 in Review

Tibra Equities Europe sold out of TherapeuticsMD (TXMD) in Q2 2019, closing a stake of 3,354 shares — an estimated $817K sold.

Tibra Equities Europe first reported a position in TXMD in Q1 2019 and held it in 1 quarter. The position peaked at $817K in Q1 2019. 148 funds tracked by Wall St. Rank hold TXMD as of Q2 2019.

  • Tibra Equities Europe reported no remaining TherapeuticsMD position as of Q2 2019 after selling out during the quarter.
  • Tibra Equities Europe sold 3,354 TherapeuticsMD shares in Q2 2019, an estimated $817K.
  • Tibra Equities Europe first reported a position in TherapeuticsMD in Q1 2019 and held it in 1 quarter.
  • Tibra Equities Europe's TherapeuticsMD position peaked at $817K in Q1 2019.
  • 148 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2019.

Based on Tibra Equities Europe's 13F filing for Q2 2019, filed 1 Aug 2019.